DeepCure, a company developing laparoscopic renal denervation (RDN) devices, announced on the 14th that it participated in the 41st World Congress of Endourology and Uro-Technology 2024 (WCET 2024).
WCET 2024 is an international academic conference hosted by the World Endourology Society. It gathers expert professors and medical professionals from around the world to share specialized knowledge and treatment methods related to urological diseases. This year, in collaboration with the Korean Society of Endourology and Robotics (KSER), the event was held for five days from the 12th at COEX in Seoul.
At this conference, the company participated as a sponsor in the Semi-live Surgery Session to introduce laparoscopic RDN. Changwook Jung, founder of DeepCure and professor at Seoul National University Hospital, presented on the second day about "Laparoscopic renal denervation for refractory Hypertension: Foundations and Preclinical studies" and "Laparoscopic renal denervation for refractory Hypertension: First in human trial."
On the third day, Jeonggi Cho, a professor at Hanyang University Hospital who participated in the domestic clinical trials of laparoscopic RDN, explained "Extravascular laparoscopic renal denervation in patients with resistant hypertension: Experience from first in human trial in Korea."
In particular, the company revealed domestic clinical results of the laparoscopic RDN medical device "HyperQure™," attracting high interest from leading scholars in global endourology. The company successfully completed four clinical surgeries this year, demonstrating the safety and efficacy of HyperQure. All patients who participated in the clinical trials had their blood pressure controlled within the normal range immediately after the laparoscopic RDN surgery and were discharged in good health.
A company representative stated, "HyperQure is the world's first medical device that treats resistant hypertension by blocking the sympathetic nerves around the renal artery using a laparoscopic method," adding, "Along with ongoing domestic clinical trials, we are preparing to enter global clinical trials targeting the second half of this year." They also said, "We will actively participate in various events in the future to promote the advanced technology of HyperQure."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
